PARSHALL B LYNNE 4

What Happened
B. Lynne Parshall, a director of Ionis Pharmaceuticals, sold 5,000 shares in an open-market transaction on February 11, 2026. The weighted-average sale price was $82.72 per share for total proceeds of $413,588. This was a sale (not a purchase), which is often routine insider selling.

Key Details

• Transaction date: 2026-02-11; Form 4 filed: 2026-02-13 (appears timely).
• Price: weighted average $82.72; individual trades ranged from $82.585 to $82.97.
• Shares sold: 5,000; total proceeds reported: $413,588.
• Shares owned after transaction: not specified in the provided filing details.
• Footnote F1: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted May 6, 2025.
• Footnote F2: The reported price is a weighted average; the filer will provide a breakdown of the number of shares sold at each price upon request.

Context
Sales made under a 10b5-1 plan are pre-arranged trading programs that allow insiders to sell shares according to a preset schedule and are generally viewed as routine rather than a direct signal of management’s view. This filing reports a straightforward open-market sale; no option exercises, gifts, or tax-withholding transactions are indicated.